ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADMA Biologics, Inc. on February 25, 2021. The report details the Board of Directors' approval of 2021 base salaries and performance-based compensation for named executive officers, effective as of the report date.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data presented relates to executive compensation:
- CEO (Adam S. Grossman): 2021 Base Salary of $618,000; Total Bonus of $486,000 (comprising $396,000 cash and $90,000 in RSUs).
- CSO/CMO (Dr. James Mond): 2021 Base Salary of $453,200; Total Bonus of $233,200 (comprising $211,200 cash and $22,000 in RSUs).
- CFO (Brian Lenz): 2021 Base Salary of $432,600; Total Bonus of $222,600 (comprising $201,600 cash and $21,000 in RSUs).
- Stock Price: The grant date fair market value of Common Stock was $2.35 per share.
Material Changes and Performance
The compensation awards reflect a performance evaluation indicating the Company achieved 95% of its 2020 corporate goals and milestones. Additionally, an extra 25% bonus achievement was granted for specific corporate accomplishments, including debt refinancing and other financial and operating overachievements.
Outlook, Risks, and Unusual Items
Compensation Structure:
- Cash Bonuses: Scheduled for payment in March 2021.
- Restricted Stock Units (RSUs): Granted on February 25, 2021. Bonus RSUs vest in a cliff structure (1/3 annually over 3 years). Annual incentive RSUs vest quarterly over four years.
- Stock Options: Granted with an exercise price of $2.35. Vesting occurs over four years (25% at one-year anniversary, remaining 75% monthly).
- Other Compensation: Includes temporary living expense payments for Dr. Mond ($8,000/month) and Mr. Lenz ($5,000/month) through December 2021, plus tax gross-ups.
Risks/Contingencies: The filing does not disclose new material risks or contingencies beyond standard vesting conditions for equity awards.
Investor Verification Checklist
- Verify the impact of the mentioned "debt refinancing" on the Company's balance sheet and interest obligations in subsequent filings (10-Q or 10-K).
- Confirm the total number of shares outstanding and the dilution effect of the 183,150 RSUs and 458,700 stock options granted to the CEO.
- Review the Company's 2020 Annual Report to validate the 95% achievement of corporate goals cited as the basis for bonuses.
- Monitor the cash outflow for the approximately $808,800 in total cash bonuses payable in March 2021.